Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acetylcholine (ACh) release at the neuromuscular junction (NMJ) is a critical process for translating motor neuron signals into muscle contraction. It involves the calcium-dependent exocytosis of ACh from presynaptic vesicles, diffusion across the synaptic cleft, binding to nicotinic acetylcholine receptors (nAChRs) on the muscle fiber, and subsequent depolarization leading to an action potential and muscle contraction. The process is tightly regulated and terminated by acetylcholinesterase. Disruptions can lead to various neuromuscular disorders.
Release of acetylcholine into the synaptic cleft, binding to nicotinic acetylcholine receptors on the muscle fiber, leading to depolarization and muscle contraction.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acetylcholine Release at Neuromuscular Junction (ACh Release (NMJ)).